Deoxycytidine kinase inactivation enhances gemcitabine resistance and sensitizes mitochondrial metabolism interference in pancreatic cancer

Abstract Pancreatic ductal adenocarcinoma (PDAC) is considered one of the most lethal forms of cancer. Although in the last decade, an increase in 5-year patient survival has been observed, the mortality rate remains high. As a first-line treatment for PDAC, gemcitabine alone or in combination (gemc...

Full description

Bibliographic Details
Main Authors: Suman Dash, Takeshi Ueda, Akiyoshi Komuro, Masahiko Honda, Ryoichi Sugisawa, Hitoshi Okada
Format: Article
Language:English
Published: Nature Publishing Group 2024-02-01
Series:Cell Death and Disease
Online Access:https://doi.org/10.1038/s41419-024-06531-x